COVID-2019 - quadrivalent seasonal influenza combined vaccine - Medigen Vaccine Biologics/Vaxess Technologies
Alternative Names: Combined COVID-19 and quadrivalent seasonal influenza vaccine; Coronavirus + Influenza Combo Patch Vaccine; Coronavirus and Influenza Combo Patch Vaccine - Medigen Vaccine Biologics/Vaxess TechnologiesLatest Information Update: 28 Oct 2024
Price :
$50 *
At a glance
- Originator Medigen Vaccine Biologics; Vaxess Technologiess
- Class COVID-19 vaccines; Influenza virus vaccines; Viral vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported COVID 2019 infections; Influenza virus infections
Most Recent Events
- 28 Oct 2024 No recent reports of development identified for preclinical development in COVID-2019-infections(Prevention) in Taiwan (Transdermal, Patch)
- 28 Oct 2024 No recent reports of development identified for preclinical development in COVID-2019-infections(Prevention) in USA (Transdermal, Patch)
- 28 Oct 2024 No recent reports of development identified for preclinical development in Influenza-virus-infections(Prevention) in Taiwan (Transdermal, Patch)